Literature DB >> 33897165

Correlation between neutrophil-to-lymphocyte ratio with Gleason score in patients with prostate cancer at Adam Malik Hospital Medan 2013 - 2015.

Michael Rulando1, Ginanda Putra Siregar1, Syah Mirsya Warli2.   

Abstract

CONTEXT: A grading system was created by Donald F. Gleason for prostate cancer as prognostic indicators. The neutrophil-to-lymphocyte ratio (NLR) was found that it could be a prognostic factor in solid tumors. AIMS: This study aims to assess whether there is a correlation between NLR with the results of the Gleason score of patients with prostate adenocarcinoma biopsy at Haji Adam Malik Hospital Medan. SETTINGS AND
DESIGN: A total of 121 patients underwent a prostate biopsy from early January 2013 to December 2015 at Adam Malik Hospital. SUBJECTS AND METHODS: Of the 121 patients, thirty were not included in the study because of incomplete baseline data and a history of hematological abnormalities. Data from 91 patients were then taken, including age, hematologic data prebiopsy, prostate-specific antigen (PSA) on initial examination, prostate weight estimation, and Gleason scores from biopsy results. STATISTICAL ANALYSIS USED: The data are processed with SPSS version 22.
RESULTS: A significant moderate strength correlation was found between NLR and Gleason Score (r = 0.572; P = 0.001). However, no statistically significant correlation found between NLR and prostate weight estimation (r = 0.077; P = 0.469) and NLR with PSA (r = 0.072; P = 0.496).
CONCLUSIONS: A significant correlation between the neutrophil-to-lymphocyte ratio and the Gleason score was noted. Further studies are needed to confirm these findings. Copyright:
© 2020 Urology Annals.

Entities:  

Keywords:  Gleason score; neutrophil-to-lymphocyte ratio; prostate cancer

Year:  2020        PMID: 33897165      PMCID: PMC8052910          DOI: 10.4103/UA.UA_1_20

Source DB:  PubMed          Journal:  Urol Ann        ISSN: 0974-7796


INTRODUCTION

Prostate cancer (PCa) is the most common malignancy in urology.[123] The increasing incidence rate was noted since the use of prostate-specific antigen (PSA), as diagnostic and therapeutic monitoring.[456] A grading system was created by Donald F. Gleason for PCa as prognostic indicators.[7] Virchow proposed that inflammation plays an essential role in the development and progression of cancer, as proved by many studies.[4589] The neutrophil-to-lymphocyte ratio (NLR) was found that it could be a prognostic factor in solid tumors.[1] This study aims to assess the correlation between NLR and the Gleason score in patients with prostate adenocarcinoma biopsy at Haji Adam Malik Hospital Medan.

SUBJECTS AND METHODS

A total of 121 patients underwent a prostate biopsy from early January 2013 to December 2015 at Adam Malik Hospital. Of the 121 patients, thirty were not included in the study because of incomplete baseline data and a history of hematological abnormalities. Data from 91 patients were then taken, including age, hematologic data prebiopsy, PSA on initial examination, prostate weight estimation, and Gleason score from biopsy results. The data are processed with SPSS version 22 (IBM Corp, Armonk, NY, USA).

RESULTS

Based on data from 91 patients, the data obtained demography characteristics are as follows. In the data [Table 1], we found patients with a mean age of 68.34 years with age ranging from 52 to 85 years. Initial PSA level with an average of 51.95 ng/mL. Measurement of Gleason score with an average of 5.9 and Gleason range of lowest score two and highest ten. In this study found NLR with an average of 7.9.
Table 1

Sample characteristic

VariableMean±SDP*
Age68.34±6.760.200
PSA51.95±39.160.000
Prostate weight estimation54.4±22.30.005
Gleason score5.9±1.520.000
NLR7.9±4.270.000

*P: Kolmogorov-Smirnov test. PSA: Prostate-specific antigen, NLR: Neutrophil-to-lymphocyte ratio, SD: Standard deviation

Sample characteristic *P: Kolmogorov-Smirnov test. PSA: Prostate-specific antigen, NLR: Neutrophil-to-lymphocyte ratio, SD: Standard deviation In the analysis with the Spearman test [Table 2], there was a significant correlation with moderate strength in which the increment of NLR score also got an improvement of Gleason Score with r = 0.572 and P = 0.001. In the analysis with the Spearman test, there is no statistically significant correlation between NLR and prostate weight estimation with r = 0.077 and P = 0.469, and also, there is no statistically significant correlation between NLR and PSA with r = 0.072 and P = 0.496.
Table 2

Correlation test results between neutrophil-to-lymphocyte ratio and Gleason score, prostate weight, prostate-specific antigen

VariablerP*
Gleason score0.5490.000
Prostate weight estimation0.0770.469
PSA0.0720.496

*Spearman test for nonparametric data. PSA: Prostate-specific antigen

Correlation test results between neutrophil-to-lymphocyte ratio and Gleason score, prostate weight, prostate-specific antigen *Spearman test for nonparametric data. PSA: Prostate-specific antigen

DISCUSSION

PCa is a frequent malignancy, with high levels of morbidity. This study founds that patients with an average PCa age of 68 years. The same result is found in Lee et al., Minardi et al., and Langsenlehner et al. study.[101112] The average value of NLR in this study is 7.9. Furthermore, the present study found that the average NLR score is 7.9, but based on a study by Langsenlehner et al., the majority of patients were in the low NLR (cut off point <5). The study by Langsenlehner et al. was performed for external validation of NLR that is used as a prognostic factor in patients with PCa, where the NLR cutoff point <5 correlated with better survival rates.[12] PSA is a marker that plays a role in early screening of PCa because PSA comes from the prostate organ. Increased PSA may occur in conditions such as prostate hypertrophy, prostatitis, or prostate manipulation (massage, instrumentation, or biopsy). However, high PSA levels are known to indicate a higher incidence of PCa.[4] In this study, all patients with PCa were found to have increased PSA. With the development of the knowledge about the mechanism of inflammatory incidence in tumors, research on the correlation between inflammatory factors, and cancer is increasingly common. Many studies have shown that the invasion ability of cancer cells is not only influenced by the biological factors of tumor cells but also influenced by the proinflammatory environment of tumors, especially interactions by various proinflammatory factors. Proinflammatory factors can primarily play a role by stimulating or suppressing tumor cells.[13] NLR, as a proinflammatory factor, has been widely studied with varying results. The modalities of therapy in PCa are based on various factors such as clinical stage, age, preoperative PSA, general patient condition, and life expectancy, but the use of the Gleason score can help to guide the therapeutic modalities to choose. Gleason score from biopsy results correlates with various pathological parameters. Tumors with higher Gleason scores had worse clinical properties and were associated with a poorer prognosis.[1415] In this study, it is found that NLR was positively correlated with the Gleason score. Our finding is consistent with the results of Gokce et al.'s study, in which NLR is associated with higher Gleason scores.[16] The study found that in the high NLR found a higher Gleason score, with higher progression rates. This supports the theory that the immune response plays an important role in patients with higher Gleason scores; where high Gleason scores are associated with greater systemic dissemination risk. Furthermore, high NLR shows an increase in neutrophils and/or decreases in lymphocytes. Neutrophils are known to respond to the release of interleukin 8 (IL-8) by tumor cells by removing enzymes that can affect the extracellular matrix. Unfortunately, this leads to angiogenesis, which is known to aid tumor development and tumor dissemination to the vascular. IL-8 is reported to be associated with aggressive properties found in PCa.[10] Besides, there was no correlation between NLR with prostate weight and serum PSA levels, as was found in other studies.[45] This research has some limitations, that is, research done retrospectively, so there is risk factor confounding factor in the sample. Furthermore, despite a reassessment of some factor factors that may affect the neutrophil-lymphocyte ratio, it is difficult to prove that the numbers obtained are only influenced by inflammation due to PCa. Furthermore, data from this study are only obtained from one institution, so the possibility of bias on pathology examination may occur.

CONCLUSIONS

Here is a significant correlation between the ratio of neutrophils/lymphocytes with the results of the Gleason score examination in PCa patients at Haji Adam Malik Hospital. Further studies are needed, whether the ratio of neutrophils/lymphocytes can be used to predict the Gleason score in patients with suspected PCa.

Financial support and sponsorship

The institution provides the funding for this study without any external funding from sponsors.

Conflicts of interest

There are no conflicts of interest.
  12 in total

1.  Role of neutrophil-to-lymphocyte ratio in prediction of Gleason score upgrading and disease upstaging in low-risk prostate cancer patients eligible for active surveillance.

Authors:  Mehmet Ilker Gokce; Semih Tangal; Nurullah Hamidi; Evren Suer; Muhammed Arif Ibis; Yasar Beduk
Journal:  Can Urol Assoc J       Date:  2016-11-10       Impact factor: 1.862

2.  High preoperative neutrophil-lymphocyte ratio predicts biochemical recurrence in patients with localized prostate cancer after radical prostatectomy.

Authors:  Hakmin Lee; Seong Jin Jeong; Sung Kyu Hong; Seok-Soo Byun; Sang Eun Lee; Jong Jin Oh
Journal:  World J Urol       Date:  2015-10-08       Impact factor: 4.226

3.  Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer.

Authors:  Young Suk Kwon; Christopher Sejong Han; Ji Woong Yu; Sinae Kim; Parth Modi; Rachel Davis; Ji Hae Park; Paul Lee; Yun-Sok Ha; Wun-Jae Kim; Isaac Yi Kim
Journal:  Clin Genitourin Cancer       Date:  2015-08-06       Impact factor: 2.872

4.  Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer.

Authors:  Daniele Minardi; M Scartozzi; L Montesi; M Santoni; L Burattini; M Bianconi; V Lacetera; G Milanese; S Cascinu; G Muzzonigro
Journal:  Springerplus       Date:  2015-06-12

Review 5.  Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Localized and Advanced Prostate Cancer: A Systematic Review and Meta-Analysis.

Authors:  Lu Tang; Xintao Li; Baojun Wang; Guoxiong Luo; Liangyou Gu; Luyao Chen; Kan Liu; Yu Gao; Xu Zhang
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

Review 6.  Neutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-Analysis.

Authors:  Jian Cao; Xuan Zhu; Xiaokun Zhao; Xue-Feng Li; Ran Xu
Journal:  PLoS One       Date:  2016-07-01       Impact factor: 3.240

Review 7.  Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients.

Authors:  Xiaobin Gu; Xianshu Gao; Xiaoying Li; Xin Qi; Mingwei Ma; Shangbin Qin; Hao Yu; Shaoqian Sun; Dong Zhou; Wen Wang
Journal:  Sci Rep       Date:  2016-02-25       Impact factor: 4.379

8.  Serum monocyte fraction of white blood cells is increased in patients with high Gleason score prostate cancer.

Authors:  Takuji Hayashi; Kazutoshi Fujita; Go Tanigawa; Atsunari Kawashima; Akira Nagahara; Takeshi Ujike; Motohide Uemura; Tetsuya Takao; Seiji Yamaguchi; Norio Nonomura
Journal:  Oncotarget       Date:  2017-05-23

9.  The prognostic significance of postoperative neutrophil-to-lymphocyte ratio after radical prostatectomy for localized prostate cancer.

Authors:  Won Sik Jang; Kang Su Cho; Myung Soo Kim; Cheol Yong Yoon; Dong Hyuk Kang; Yong Jin Kang; Won Sik Jeong; Won Sik Ham; Young Deuk Choi
Journal:  Oncotarget       Date:  2017-02-14

Review 10.  Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer: A Systematic Review and Meta-analysis.

Authors:  Xiaotao Yin; Yi Xiao; Fanglong Li; Siyong Qi; Zhaoyang Yin; Jiangping Gao
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.